Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44


Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.

Makino Y, Yoon JH, Bae E, Kato M, Miyazawa K, Ohira T, Ikeda N, Kuroda M, Mamura M.

Biochem Biophys Res Commun. 2017 Mar 4;484(2):269-277. doi: 10.1016/j.bbrc.2017.01.093. Epub 2017 Jan 20.


Phosphorylation status determines the opposing functions of Smad2/Smad3 as STAT3 cofactors in TH17 differentiation.

Yoon JH, Sudo K, Kuroda M, Kato M, Lee IK, Han JS, Nakae S, Imamura T, Kim J, Ju JH, Kim DK, Matsuzaki K, Weinstein M, Matsumoto I, Sumida T, Mamura M.

Nat Commun. 2015 Jul 21;6:7600. doi: 10.1038/ncomms8600.


Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide.

Lee YS, Park JS, Jung SM, Kim SD, Kim JH, Lee JY, Jung KC, Mamura M, Lee S, Kim SJ, Bae YS, Park SH.

EMBO Mol Med. 2015 May;7(5):577-92. doi: 10.15252/emmm.201404653.


Pathophysiological roles of cytokine-chemokine immune network.

Kwak JY, Mamura M, Barlic-Dicen J, Grage-Griebenow E.

J Immunol Res. 2014;2014:615130. doi: 10.1155/2014/615130. Epub 2014 Sep 11. No abstract available.


Proangiogenic TIE2(+)/CD31 (+) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes.

Kim OH, Kang GH, Noh H, Cha JY, Lee HJ, Yoon JH, Mamura M, Nam JS, Lee DH, Kim YA, Park YJ, Kim H, Oh BC.

Mol Cells. 2013 Nov;36(5):432-8. doi: 10.1007/s10059-013-0194-7. Epub 2013 Oct 24. Erratum in: Mol Cells. 2014 Feb;37(2):188.


Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.

Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, Sudo K, Nakae S, Han JS, Kim OH, Oh BC, Sumida T, Kuroda M, Ju JH, Jung KC, Park SH, Kim DK, Mamura M.

EMBO Mol Med. 2013 Nov;5(11):1720-39. doi: 10.1002/emmm.201302524. Epub 2013 Oct 11. Erratum in: EMBO Mol Med. 2014 May;6(5):703.


Association of variants in PPARγ², IGF2BP2, and KCNQ1 with a susceptibility to gestational diabetes mellitus in a Korean population.

Chon SJ, Kim SY, Cho NR, Min DL, Hwang YJ, Mamura M.

Yonsei Med J. 2013 Mar 1;54(2):352-7. doi: 10.3349/ymj.2013.54.2.352.


Inhibition of erythropoiesis by Smad6 in human cord blood hematopoietic stem cells.

Kang YJ, Shin JW, Yoon JH, Oh IH, Lee SP, Kim SY, Park SH, Mamura M.

Biochem Biophys Res Commun. 2012 Jul 13;423(4):750-6. doi: 10.1016/j.bbrc.2012.06.031. Epub 2012 Jun 15.


Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta.

Park HY, Wakefield LM, Mamura M.

Immune Netw. 2009 Aug;9(4):122-6. doi: 10.4110/in.2009.9.4.122. Epub 2009 Aug 31.


IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease.

Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR, Kim WJ, Han JY, Hong SS, Park SH, Lee SJ, Kim IH, Lee CR, Kim DK, Mamura M, Kim SJ, Suh JK.

J Sex Med. 2009 May;6(5):1284-96. doi: 10.1111/j.1743-6109.2009.01216.x. Epub 2009 Mar 18.


Role of increased penile expression of transforming growth factor-beta1 and activation of the Smad signaling pathway in erectile dysfunction in streptozotocin-induced diabetic rats.

Zhang LW, Piao S, Choi MJ, Shin HY, Jin HR, Kim WJ, Song SU, Han JY, Park SH, Mamura M, Kim SJ, Ryu JK, Suh JK.

J Sex Med. 2008 Oct;5(10):2318-29. doi: 10.1111/j.1743-6109.2008.00977.x. Epub 2008 Sep 5.


Absence of Smad3 induces neutrophil migration after cutaneous irradiation: possible contribution to subsequent radioprotection.

Flanders KC, Ho BM, Arany PR, Stuelten C, Mamura M, Paterniti MO, Sowers A, Mitchell JB, Roberts AB.

Am J Pathol. 2008 Jul;173(1):68-76. doi: 10.2353/ajpath.2008.070937. Epub 2008 May 23.


Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3915-23. doi: 10.1158/0008-5472.CAN-08-0206.


An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3835-43. doi: 10.1158/0008-5472.CAN-08-0215.


Intravascular large B-cell lymphoma with acute abdomen as a presenting symptom in a patient with systemic lupus erythematosus.

Ishii W, Ito S, Kondo Y, Tsuboi H, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T, Okoshi Y, Hasegawa Y, Kojima H, Sakashita S, Aita K, Noguchi M.

J Clin Oncol. 2008 Mar 20;26(9):1553-5. doi: 10.1200/JCO.2007.14.5847. No abstract available.


Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.

Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T.

Arthritis Rheum. 2008 Mar;58(3):754-63. doi: 10.1002/art.23222.


Interleukin-17 gene expression in patients with rheumatoid arthritis.

Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T.

Mod Rheumatol. 2008;18(1):15-22. Epub 2007 Dec 20.


Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.

Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J, Parks WT, Wakefield LM.

Cancer Res. 2007 Sep 15;67(18):8643-52.


Biased usage of synovial immunoglobulin heavy chain variable region 4 by the anti-glucose-6-phosphate isomerase antibody in patients with rheumatoid arthritis.

Hayashi T, Matsumoto I, Yasukochi T, Mamura M, Goto D, Ito S, Tsutsumi A, Sumida T.

Int J Mol Med. 2007 Aug;20(2):247-53.


Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13.

Enami T, Suzuki T, Ito S, Yoshimi A, Sugihara M, Mamura M, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Sumida T.

Intern Med. 2007;46(13):1033-7. Epub 2007 Jul 2.


Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis.

Sugihara M, Tsutsumi A, Suzuki E, Wakamatsu E, Suzuki T, Ogishima H, Hayashi T, Chino Y, Ishii W, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T.

Arthritis Rheum. 2007 Jul;56(7):2160-9.


Sarcoid myositis with muscle weakness as a presenting symptom.

Yamada H, Ishii W, Ito S, Iwanami K, Ogishima H, Suzuki T, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.

Mod Rheumatol. 2007;17(3):243-6. Epub 2007 Jun 20.


Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.

Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.

Intern Med. 2007;46(11):771-4. Epub 2007 Jun 1.


Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sjögren's syndrome.

Wakamatsu E, Matsumoto I, Yasukochi T, Naito Y, Goto D, Mamura M, Ito S, Tsutsumi A, Sumida T.

Arthritis Rheum. 2006 Nov;54(11):3476-84.


Identification of three novel peptides that inhibit CD40-CD154 interaction.

Kitagawa M, Goto D, Mamura M, Matsumoto I, Ito S, Tsutsumi A, Sumida T.

Mod Rheumatol. 2005;15(6):423-6.


Expression of TNF-alpha, tristetraprolin, T-cell intracellular antigen-1 and Hu antigen R genes in synovium of patients with rheumatoid arthritis.

Suzuki E, Tsutsumi A, Sugihara M, Mamura M, Goto D, Matsumoto I, Ito S, Ikeda K, Ochiai N, Sato Y, Sumida T.

Int J Mol Med. 2006 Aug;18(2):273-8.


Smad4 signalling in T cells is required for suppression of gastrointestinal cancer.

Kim BG, Li C, Qiao W, Mamura M, Kasprzak B, Anver M, Wolfraim L, Hong S, Mushinski E, Potter M, Kim SJ, Fu XY, Deng C, Letterio JJ.

Nature. 2006 Jun 22;441(7096):1015-9. Erratum in: Nature. 2006 Dec 7;444(7120):780. Kasperczak, Barbara [corrected to Kasprzak, Barbara].


Diagnosis of chlamydia-induced reactive arthritis.

Ito S, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.

Intern Med. 2006;45(1):37. Epub 2006 Feb 1. No abstract available.


TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation.

Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, Shevach EM, Piccirillo CA.

Eur J Immunol. 2005 Oct;35(10):2886-95.


Loss of Smad3 in acute T-cell lymphoblastic leukemia.

Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ.

N Engl J Med. 2004 Aug 5;351(6):552-9.


CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1.

Mamura M, Lee W, Sullivan TJ, Felici A, Sowers AL, Allison JP, Letterio JJ.

Blood. 2004 Jun 15;103(12):4594-601. Epub 2004 Mar 11.


Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA.

J Exp Med. 2003 Dec 1;198(11):1741-52.


CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness.

Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, Shevach EM.

J Exp Med. 2002 Jul 15;196(2):237-46.


Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells.

Kim HT, Kim BC, Kim IY, Mamura M, Seong DH, Jang JJ, Kim SJ.

J Biol Chem. 2002 Sep 6;277(36):32510-5. Epub 2002 Jun 25.


Tumor necrosis factor induces apoptosis in hepatoma cells by increasing Ca(2+) release from the endoplasmic reticulum and suppressing Bcl-2 expression.

Kim BC, Kim HT, Mamura M, Ambudkar IS, Choi KS, Kim SJ.

J Biol Chem. 2002 Aug 30;277(35):31381-9. Epub 2002 Jun 20.


Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.

Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM.

J Clin Invest. 2002 Jun;109(12):1607-15.


Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells.

Inagaki Y, Mamura M, Kanamaru Y, Greenwel P, Nemoto T, Takehara K, Ten Dijke P, Nakao A.

J Cell Physiol. 2001 Apr;187(1):117-23.


Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation.

Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2587-92. Epub 2001 Feb 20.


Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis.

Kanamaru Y, Nakao A, Mamura M, Suzuki Y, Shirato I, Okumura K, Tomino Y, Ra C.

J Immunol. 2001 Feb 15;166(4):2818-23.


Ligation of the T cell receptor complex results in phosphorylation of Smad2 in T lymphocytes.

Mamura M, Nakao A, Goto D, Kato M, Saito Y, Iwamoto I.

Biochem Biophys Res Commun. 2000 Feb 5;268(1):124-7.


Tumor necrosis factor-alpha mediates antiapoptotic signals partially via p38 MAP kinase activation in human eosinophils.

Tsukahara K, Nakao A, Hiraguri M, Miike S, Mamura M, Saito Y, Iwamoto I.

Int Arch Allergy Immunol. 1999;120 Suppl 1:54-9.


Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells.

Inaba M, Kurasawa K, Mamura M, Kumano K, Saito Y, Iwamoto I.

J Immunol. 1999 Aug 1;163(3):1315-20.

Supplemental Content

Loading ...
Support Center